Table 4 Safety for use of common prescribed drugs for women with diabetes during pregnancy and breastfeeding.
From: Dysglycemias in pregnancy: from diagnosis to treatment. Brazilian consensus statement
Drug | Safety for use during pregnancy | Safety for use during lactation | Level of evidence |
|---|---|---|---|
SWEETENERS | |||
aspartame, saccharin, acesulfame-K and sucralose | Moderately | moderately | C |
ORAL ANTIHYPERGLICEMIC AGENTS | |||
Glibenclamide | No consensus | Yes | B |
Glicazide | No | No | B |
Glipizide | No | Yes | B |
Glimepiride | No | No | B |
Metformin | No consensus | Yes | B |
Acarbose | No | No | C |
Rosi and pioglitazone | No | No | C |
Sita and vildagliptin | No | No | C |
Exenatide | No | No | D |
INSULIN | |||
NPH | Yes | Yes | A |
Regular | Yes | Yes | A |
Lispro | Yes | Yes | B |
Aspart | Yes | Yes | B |
Gargine | No consensus | No consensus | C |
Detemir | No consensus | No consensus | C |
ORAL ANTIHYPERLIPIDEMIC AGENTS | |||
Gemfibrozil | No | No | A |
Statins | No | No | A |
ANTIHYPERTENSIVE | |||
Enalapril | No | With caution | A |
Captopril | No | No | A |
Lisinopril | No | No | A |
Methyldopa | Yes | Yes | A |
Losartan | No | With caution | A |
Candesartan | No | No | A |
Hydrochlorothiazide (low doses) | Yes | Yes | C |
Calcium channel Inhibitors | No | Yes | C |
Beta- blockers(labetalol, metoprolol, propanolol) | Yes | Yes | B |
Atenolol | No | No | A |
THYROID HORMONES | |||
Levothyroxine | Yes | Yes | A |
ANTITHYROID DRUGS | |||
Methimazole | With caution | Yes | B |
Propiltiouracil | Yes | Yes | B |
Iodine | No | No | A |
ANTIDEPRESSANTS | |||
Fluoxetine | No | No | B |
Paroxetine | With caution | Yes | B |
Tricyclic(amytriptyline, nortriptyline, clomipramine) | With caution | Yes | B |
ANTI-INFLAMMATORY DRUGS | |||
Nimesulide | With caution | With caution | B |
Mefenamic acid, ketoprofen, diclofenac, ibuprofen, meloxicam | With caution | Yes | B |
Analgesics | |||
Acetaminophen | Yes | Yes | B |
Antibiotics | |||
Quinolones(norfloxacin, moxifloxacin, ciprofloxacin) | No | No | C |